ADPD 2023 Conference Highlights - Part 2
This year’s AD/PD Conference was held in Gothenburg, Sweden from the 28th March to 1st April. In this second of a two-part special we bring you highlights from last three days of the conference. The AD/PD Conference focuses on basic science and translational and clinical research bringing New insights on disease mechanisms and etiologies, the latest findings from clinical trials, innovative outlooks on therapy and prevention and advances in diagnostic markers. In this special on-location recording our guest host Dr Anna Mallach, Research Fellow from the UK Dementia Research Institute at University College London talks with: Dr Melissa Scholefield, Postdoctoral Research Associate at University of Manchester. Melissa focusses on undertaking Multi-omic analysis of Lewy body dementias. Dr Chi Udeh-Momoh, Research Programme and Biomarker Lead at Imperial College London. Chi has always been fascinated by the brain, how we think, learn and remember; and how these processes can be affected in disease/ alleviated therapeutically. Emily McCann, PhD Student at Queensland Brain Institute, University of Queensland. Emily’s research is in cognitive test development for neurodegenerative diseases. She aims to align functional neural changes with the patient cognitive profile, and has developed a series of tests to measure visuoperceptual impairments in patients with Alzheimer's and Lewy Body pathology. For more information on the event visit: https://adpd.kenes.com/ Full biographies on all our guests and a transcript can be found on our website: https://www.dementiaresearcher.nihr.ac.uk Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you’ll find a video version of this podcast on our YouTube Channel and in Spotify: https://youtu.be/W8kj7PqHz98 This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer’s Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.